Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 27, 2015 10:42 AM ET

Biotechnology

Company Overview of Tobira Therapeutics, Inc.

Company Overview

Tobira Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapeutics to treat liver diseases, human immunodeficiency virus (HIV)-1, kidney fibrosis, and inflammation. It offers cenicriviroc, an immumodulator and dual inhibitor of CCR2 and CCR5 for the treatment of non-alcoholic steatohepatitis (NASH), HIV, and others. The company was founded in 2006 and is based in South San Francisco, California.

701 Gateway boulevard

Suite 200

South San Francisco, CA 94080

United States

Founded in 2006

13 Employees

Phone:

650-741-6625

Key Executives for Tobira Therapeutics, Inc.

Executive Chairman and Chief Executive Officer
Age: 50
Founder and Director
Age: 64
Chief Financial Officer, Principal Financial & Accounting Officer and Head of Corporate Development
Age: 35
Chief Operating Officer
Age: 50
Chief Medical Officer
Age: 50
Compensation as of Fiscal Year 2014.

Tobira Therapeutics, Inc. Key Developments

Tobira Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Tobira Therapeutics, Inc. filed its PREM14A on Mar 06, 2015 for the period ending Dec 31, 2014. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Tobira Therapeutics Doses First Subject in Phase 1 Clinical Trial of Cenicriviroc and Pioglitazone

Tobira Therapeutics, Inc. announced that it has dosed the first subject in a Phase 1 study to evaluate the pharmacokinetics and safety in healthy subjects of cenicriviroc (CVC) and the diabetes medication pioglitazone, both when administered alone and in combination. The study supports Tobira's larger clinical program of CVC in non-alcoholic steatohepatitis (NASH), a disease associated with multiple comorbidities, including diabetes. Pioglitazone is approved to improve glycemic control in patients with Type 2 diabetes mellitus and has previously been studied in NASH. In addition, Tobira believes that the eventual approach to treating NASH will include multiple therapies to address the comorbidities of NASH, including Type 2 diabetes.

Regado Biosciences, Inc., Tobira Therapeutics, Inc. - M&A Call

To discuss the merger agreement

Similar Private Companies By Industry

Company Name Region
Surfacine Development Company LLC United States
iDiverse, Inc. United States
Annovis, Inc. United States
Cytopeia, Inc. United States
ENDECE, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
January 14, 2015
Regado Biosciences, Inc.
Private Placement
January 14, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tobira Therapeutics, Inc., please visit www.tobiratherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.